202 completed, 38 terminated, 37 unknown, 16 recruiting. 145 Phase 1, 102 Phase 2, 46 Not applicable, 25 Phase 3, 4 Early Phase 1.
Follow this condition Literature Review of Lymphadenopathy trials Research Report on Lymphadenopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MBLA to Differentiate IRIS From Treatment Failure in Extrapulmonary Tuberculosis MBLA from routine lymph node aspirate - Extrapulmonary Tuberculosis | Not yet recruiting | Research Center Borstel | 100 | 2026-09-01 | 2026-08-31 | |
| Longitudinal Prognosis of Lymphoproliferative Manifestations in Primary Immunodeficiencies Primary Immune Deficiencies, Benign Lymphoproliferative Disorder | Not yet recruiting | Central Hospital, Nancy, France | 60 | 2026-04-01 | 2026-04-13 | |
| Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma PET-CTandct- DNAdetection, golidocitinib, Placebo - Maintenance Treatment of Peripheral T-cell Lymphoma | Phase 3 | Recruiting | Fudan University | 136 | 2026-03-27 | 2026-03-31 |
| Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma azacitidine, abatacept - Lymphoma, T Cell, Peripheral, T-cell Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 20 | 2026-03-26 | 2026-10-20 |
| A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) Cyclophosphamide, Fludarabine, Autologous CCR4 CAR T cells - Relapsed and/or Refractory Mature T Cell Malignancy, Peripheral T-Cell Lymphoma | Phase 1 | Suspended | National Cancer Institute (NCI) | 60 | 2025-09-29 | 2026-10-16 |
| A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma Brincidofovir - Relapsed or Refractory Lymphoma Including ENKL | Phase 1 / Phase 2 | Suspended | SymBio Pharmaceuticals | 43 | 2025-06-09 | 2026-02-05 |
| A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype Duvelisib, Gemcitabine, Bendamustine - Lymphoma | Phase 3 | Recruiting | SecuraBio | 124 | 2025-05-19 | 2026-04-06 |
| A Clinical Study on the Feasibility and Safety of Abdominal Endoscopic Single-port Surgery System to Assist Gynecological Day Surgery Domestic single-port laparoscopic surgery system - Adenopathy, Uterine Fibroids | Not applicable | Not yet recruiting | Second Affiliated Hospital of Wenzhou Medical University | 63 | 2025-04-10 | 2025-04-03 |
| EBUS-TTFB vs EBUS-TBNA for Diagnosing Inadequate Lymph Node Specimens Based on MOSE EBUS-TBNA, EBUS-TTFB - Lymphadenopathy | Not applicable | Recruiting | Shanghai Chest Hospital | 162 | 2025-04-01 | 2025-04-18 |
| New Approaches for the Diagnosis of Lymphoma and Multicentric Castleman Disease Lymph Node or Core Needle Biopsy, Fine Needle Aspiration, Tiny Isothermal Nucleic acid Amplification System (TINY) - HIV, Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease | Not applicable | Recruiting | Indiana University | 500 | 2025-03-17 | 2026-08-28 |
| Tazemetostat Plus CHOP in 1L T-cell Lymphoma Tazemetostat, Doxorubicin, Vincristine - Lymphoma, Peripheral T Cell Lymphoma | Phase 2 | Withdrawn | Eric Jacobsen, MD | 2024-12-24 | 2026-04-01 | |
| Value of Super-resolution Ultrasonography in Differentiating Benign and Malignant Lymph Nodes SRUS imaging of the lymph nodes before surgery or biopsy - Lymphadenopathy, Lymphnode Metastasis | Recruiting | Peking University Third Hospital | 779 | 2024-10-23 | 2025-09-04 | |
| Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma Soquelitinib, Belinostat, Pralatrexate - Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma | Phase 3 | Recruiting | Corvus Pharmaceuticals, Inc. | 150 | 2024-10-02 | 2026-09-25 |
| A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. ARV-393, Glofitamab - Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL) | Phase 1 | Recruiting | Arvinas Inc. | 329 | 2024-09-05 | 2026-09-04 |
| Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma Fenretinide - T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma | Phase 1 | Recruiting | SciTech Development, Inc. | 46 | 2023-12-18 | 2026-10-05 |
| Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL mitoxantrone liposome 16 and azacitidine, mitoxantrone liposome 18 and azacitidine, mitoxantrone liposome 20 and azacitidine - Angioimmunoblastic T-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huijing Wu | 30 | 2023-12-12 | 2024-01-25 |
| LN-RADS, RECIST 1.1 and Node-RADS Classification in the Assessment of Lymph Nodes Lymph node assessment according to RECIST 1.1 in CT, Lymph node assessment according to Node-RADS in CT, Lymph node assessment according to LN-RADS in CT - Lymph Node Neoplasm, Lymph Node Metastasis | Not applicable | Recruiting | Copernicus Memorial Hospital | 1000 | 2023-12-01 | 2025-12-30 |
| A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) BMS-986369 - Relapsed or Refractory T-cell Lymphomas | Phase 1 / Phase 2 | Active not recruiting | Bristol-Myers Squibb | 83 | 2023-11-20 | 2026-10-07 |
| Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight CEP + Dasatinib + Azacitidine - Angioimmunoblastic T-cell Lymphoma (AITL) | Phase 4 | Active not recruiting | Zhengzhou University | 34 | 2023-10-21 | 2025-07-01 |
| Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies WU-CART-007 - T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia | Phase 1 | Suspended | Washington University School of Medicine | 6 | 2023-10-10 | 2026-07-21 |
Showing 20 of 327. Sign in to see all of them.
Immunoblastic Lymphadenopathy (272) · Lymphoma, Large-Cell, Anaplastic (239) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (202) · Lymphoma, Large B-Cell, Diffuse (199) · Leukemia, Lymphocytic, Chronic, B-Cell (189) · Lymphoma, Follicular (188) · Lymphoma, Mantle-Cell (185) · Burkitt Lymphoma (182) · Lymphoma, B-Cell, Marginal Zone (182) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (180) · Lymphoma, Non-Hodgkin (178) · Lymphoma, T-Cell, Cutaneous (177) · Hodgkin Disease (174) · Mycosis Fungoides (173) · Lymphoma, Large-Cell, Immunoblastic (167)
Hemic and Lymphatic Diseases (327) · Lymphatic Diseases (326) · Immune System Diseases (296) · Immunoproliferative Disorders (289) · Neoplasms by Histologic Type (285) · Neoplasms (277) · Lymphoproliferative Disorders (258) · Hematologic Diseases (225) · Leukemia, Lymphoid (219) · Pathological Conditions, Signs and Symptoms (216) · Lymphoma, T-Cell (214) · Pathologic Processes (210) · Lymphoma, B-Cell (206) · Disease Attributes (204)
Cyclophosphamide (39) · fludarabine phosphate (27) · Peripheral Blood Stem Cell Transplantation (25) · Doxorubicin (19) · Etoposide (19) · Prednisone (18) · Vincristine (18) · Whole-Body Irradiation (18) · Cyclosporine (16) · Mycophenolic Acid (16) · Bortezomib (13) · Rituximab (13) · Busulfan (12) · Tacrolimus (12) · Antilymphocyte Serum (11)
National Cancer Institute (NCI) (44) · Fred Hutchinson Cancer Center (15) · City of Hope Medical Center (12) · M.D. Anderson Cancer Center (12) · Mayo Clinic (12) · Memorial Sloan Kettering Cancer Center (10) · Northwestern University (8) · Case Comprehensive Cancer Center (7) · National Institutes of Health Clinical Center (CC) (7) · European Organisation for Research and Treatment of Cancer - EORTC (6) · Jonsson Comprehensive Cancer Center (6) · Roswell Park Cancer Institute (5) · University of Medicine and Dentistry of New Jersey (5) · Wake Forest University Health Sciences (5) · Barbara Ann Karmanos Cancer Institute (4)
United States (238) · China (26) · Italy (19) · Germany (16) · France (14) · Canada (12) · United Kingdom (12) · Belgium (8) · Netherlands (6) · South Korea (6) · Switzerland (6) · Spain (5) · Taiwan (4) · Australia (3) · Czechia (3)
David Maloney (4) · Shivaani Kummar, MD (4) · Ajay Gopal (3) · Brenda Sandmaier (3) · John A. Glaspy, MD, MPH (3) · Roger Strair, MD, PhD (3) · Thomas E. Witzig, MD (3) · Abhinav Deol, M.D. (2) · Alex F Herrera (2) · Ann Woolfrey (2) · Barbara Pro, MD (2) · Craig C. Hofmeister, MD (2) · David G. Savage, MD (2) · David J. Straus, MD (2) · David R. Spriggs, MD (2)
PMID 32499241, PMID 10228757, PMID 11410496, PMID 12525530, PMID 14630685, PMID 15459300, PMID 15855973, PMID 16135477, PMID 16148284, PMID 16710026, PMID 17119113, PMID 17397698, PMID 17643700, PMID 18226581, PMID 18327587, PMID 18463792, PMID 18494054, PMID 18698002, PMID 19117242, PMID 19170225, PMID 19451403, PMID 19693943, PMID 19789320, PMID 19841031, PMID 19900571, PMID 20142598, PMID 20166206, PMID 20229590, PMID 20802352, PMID 20942843, PMID 21135857, PMID 21247755, PMID 21299803, PMID 21420083, PMID 21487108, PMID 21498721, PMID 21715313, PMID 22156610, PMID 22259028, PMID 22284089, PMID 22337718, PMID 22480131, PMID 23256542, PMID 23335369, PMID 23358983, PMID 23393050, PMID 23433596, PMID 23433878, PMID 24057042, PMID 24174627
P30CA015704 (12), P30CA015083 (8), P30CA016672 (8), P30CA033572 (8), P30CA072720 (6), P30CA043703 (5), P01CA018029 (4), P30CA036727 (4), U01CA062491 (4), U01CA076576 (4), U01CA099168 (4), U10CA032102 (4), P30CA006973 (3), P30CA014520 (3), P30CA016058 (3)